Hims & Hers Director Bets $1.2M as GLP-1 Battle Heats Up

NEW YORK, June 17 —

Hims & Hers Health stock is rising Tuesday despite fresh anxiety over Amazon's push into GLP-1 drugs. The move follows a volatile May: a 13% post-earnings plunge, then a company director's $1.17 million open-market purchase near the lows, and two new material financial obligations filed quietly with the SEC.

Thirteen Percent in One Day

Hims & Hers filed first-quarter results on May 11, disclosing a loss and guidance that disappointed investors. CNBC reported the stock fell 13% on the news; Reuters traced the damage to the company's pivot toward branded weight-loss drugs, which per that reporting is weighing on near-term results as the competitive field widens around it.

The competitive pressure is real. Amazon's move involving Ozempic, cited as part of its escalating push into the GLP-1 market, signals that the category Hims & Hers has oriented itself around is drawing a formidable new entrant. For a telehealth company whose differentiation depends on GLP-1 access and compounding, a hyperscaler entering pharmacy delivery is a structural challenge.

Buying Into the Wreckage

Two weeks after the selloff, director David B Wells stepped in. On May 26, he purchased 48,400 shares at $24.23 each, spending $1,172,974 in a single open-market transaction. The purchase came after the stock had absorbed the post-earnings shock but remained well below where it trades today.

Board-level open-market purchases at this scale carry real signal. Directors have no obligation to buy. Committing $1.2 million into a stock that just fell 13% reflects either conviction that the selloff overshot or a longer-term bet on the GLP-1 and peptide opportunity that near-term results don't capture. Leerink analysts have flagged the peptide strategy as a source of long-term upside, though they maintain a Neutral rating on the stock.

What the CFO Did First

The insider picture is more layered than the headline purchase suggests. Eight days before Wells bought, CFO Oluyemi Okupe sold 7,950 shares at $23.64, generating approximately $187,916. Executive sales are often programmatic, but the sequence is worth holding in view: the CFO was trimming as the stock sat near post-earnings lows, while the director moved in the opposite direction days later.

Across all insider activity over the past 90 days, open-market purchases of approximately $1.17 million outpace sales of approximately $470,000. The net-buying posture tilts directionally positive, though the gap is driven almost entirely by Wells' single transaction.

Two New Obligations

While the insider moves drew attention, Hims & Hers was also active in capital markets. A May 21 8-K disclosed a material definitive agreement, a new direct financial obligation, and unregistered sales of equity securities — a structure that typically indicates a private placement or convertible instrument. A June 2 8-K disclosed a second material agreement and financial obligation. The filing headers don't detail the counterparties or terms; the substance awaits further disclosure.

Two capital transactions in six weeks, both creating new financial obligations, add complexity to a balance sheet already navigating a strategic pivot and a competitive reset.

What to Watch

Three things will shape the story from here. First, how Amazon's GLP-1 strategy develops: a move from Ozempic adjacency into compounded semaglutide or telehealth prescribing would directly narrow Hims & Hers' positioning. Second, execution on the peptide roadmap that Leerink flagged as the long-term upside case. Third, the valuation: at $32.06, HIMS already trades above the consensus analyst price target of $26.61, at a forward P/E of 36 times. The market is pricing in a growth trajectory beyond current sell-side consensus; whether the branded weight-loss pivot and peptide strategy deliver it is the central question.

Run the free Hims & Hers Health, Inc. deep-dive →

Basis Report does not hold positions in securities discussed. This is not investment advice.

Frequently Asked Questions

Why is Hims & Hers stock going up today?

Hims & Hers stock is rising Tuesday per Benzinga, recovering from a volatile May in which shares fell 13% following weak first-quarter results and guidance. The rebound comes alongside renewed focus on the company's longer-term GLP-1 and peptide strategy.

Did insiders buy or sell HIMS stock recently?

en-market purchase on May 26, buying 48,400 shares at $24.23 each. CFO Oluyemi Okupe sold approximately $187,916 in shares eight days earlier, on May 18. Net across the past 90 days, open-market purchases of approximately $1.17 million outpace sales of approximately $470,000.

How does Amazon entering GLP-1 affect Hims & Hers?

Amazon's escalating push into the GLP-1 market, including a move involving Ozempic, represents a structural competitive threat to Hims & Hers' telehealth and weight-loss drug access model. For a company pivoting toward branded GLP-1 drugs, a hyperscaler entering pharmacy delivery narrows the differentiation case.

What is the analyst price target for HIMS stock?

The consensus analyst price target on Hims & Hers is $26.61, below the current trading price of $32.06. Leerink analysts maintain a Neutral rating while flagging long-term upside from the company's peptide strategy.

What are the new 8-K filings Hims & Hers made in May and June 2026?

Hims & Hers filed two 8-Ks disclosing material definitive agreements and new direct financial obligations. The May 21 filing also covered unregistered equity securities, suggesting a private placement or convertible structure. A second filing on June 2 covered another agreement and financial obligation; full terms are not detailed in the filing headers.